Hims & Hers Health, Inc. (HIMS)
NYSE: HIMS · Real-Time Price · USD
29.79
+1.09 (3.80%)
At close: Sep 30, 2026, 4:00 PM EDT
29.95
+0.16 (0.54%)
Pre-market: Oct 1, 2026, 6:31 AM EDT
Hims & Hers Health Revenue
Hims & Hers Health had revenue of $753.21M in the quarter ending June 30, 2026, with 38.25% growth. This brings the company's revenue in the last twelve months to $2.58B, up 28.04% year-over-year. In the year 2025, Hims & Hers Health had annual revenue of $2.35B with 59.00% growth.
Revenue (ttm)
$2.58B
Revenue Growth
+28.04%
P/S Ratio
2.70
Revenue / Employee
$1,055,738
Employees
2,442
Market Cap
6.95B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.35B | 871.12M | 59.00% |
| Dec 31, 2024 | 1.48B | 604.51M | 69.33% |
| Dec 31, 2023 | 872.00M | 345.08M | 65.49% |
| Dec 31, 2022 | 526.92M | 255.04M | 93.81% |
| Dec 31, 2021 | 271.88M | 123.12M | 82.77% |
| Dec 31, 2020 | 148.76M | 66.20M | 80.18% |
| Dec 31, 2019 | 82.56M | 55.88M | 209.45% |
| Dec 31, 2018 | 26.68M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Elanco Animal Health | 5.02B |
| Dr. Reddy's Laboratories | 3.50B |
| Neurocrine Biosciences | 3.37B |
| Amneal Pharmaceuticals | 3.12B |
| Alkermes | 1.67B |
| Lantheus Holdings | 1.56B |
| Indivior Pharmaceuticals | 1.33B |
| Kiniksa Pharmaceuticals International, | 840.85M |
HIMS News
- 14 hours ago - Kaplan Fox Urges Investors of Hims & Hers Health, Inc. (HIMS) to Seek a Leadership Role Before November 2, 2026 - Newsfile Corp
- 19 hours ago - Kaplan Fox Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors to Contact the Firm Before the Lead Plaintiff Deadline on November 2, 2026 - GlobeNewsWire
- 1 day ago - Kaplan Fox Encourages Hims & Hers Health, Inc. (HIMS) Investors Seeking Recovery to Contact the Firm Before November 2, 2026 - Newsfile Corp
- 5 days ago - HIMS Stockholders Have Rights – If You Lost Money Investing in Hims & Hers Health, Inc. Contact Robbins LLP for Information About Recovering Your Losses - GlobeNewsWire
- 7 days ago - Kaplan Fox Notifies Hims & Hers Health, Inc. (NYSE: HIMS) Investors of an Upcoming Lead Plaintiff Deadline on November 2, 2026 - GlobeNewsWire
- 7 days ago - FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow. - Market Watch
- 8 days ago - Kaplan Fox Alerts Hims & Hers Health, Inc. (HIMS) Investors to an Approaching Lead Plaintiff Deadline on November 2, 2026 - Newsfile Corp
- 12 days ago - Kaplan Fox Reminds Hims & Hers Health, Inc. (HIMS) Investors to Seek a Leadership Role Before Deadline on November 2, 2026 - Newsfile Corp